The novel selective cardiac myosin activator omecamtiv mecarbil improves diastolic function and pulmonary pressures without adversely affecting diastolic filling in patients with chronic heart failure (HF) and reduced systolic function, the COSMIC-HF* trial has shown.
An invasive strategy, on top of optimal medical therapy (OMT), is no better than OMT alone in preventing cardiovascular (CV) events in patients with stable, moderate-to-severe coronary artery disease (CAD), the largest randomized trial to date of an invasive vs conservative strategy, ISCHAEMIA*, has shown. This, the cardiologist world sees as a monumental achievement that is set to change practice.
Icosapent ethyl (IPE), a purified form of the omega-3 fatty acid eicosapentaenoic acid (EPA), slowed the progression of plaque in statin-treated patients with coronary atherosclerosis, according to the interim results of the EVAPORATE* trial presented at AHA 2019.
Multiple analyses of the DAPA-HF* trial have shown that dapagliflozin, in addition to standard therapy, reduces the risk of multiple heart failure (HF) outcomes including cardiovascular (CV) death and hospitalization for HF (HHF) in patients with HF and reduced ejection fraction (HFrEF), with the effects consistent regardless of age and type 2 diabetes (T2D) status.
The impact of sacubitril plus valsartan compared with valsartan alone in reducing heart failure hospitalizations (HHF) in individuals with heart failure with preserved ejection fraction (HFpEF) appears to be greater in women than men, according to a subgroup analysis of the PARAGON-HF* trial.
Twice-a-year injections of the small interfering RNA (siRNA) inclisiran significantly reduced low-density lipoprotein cholesterol (LDL-C) levels in patients with atherosclerotic cardiovascular disease (ASCVD) who have insufficient LDL-C reductions despite maximum oral lipid-lowering therapy, the ORION-10* trial showed.
Immediate coronary angiography does not improve survival at 1 year in patients who were successfully resuscitated from an OHCA* without ST-segment elevation myocardial infarction (STEMI) compared with delayed coronary angiography, according to the COACT** trial presented at AHA 2019.
A target low-density lipoprotein cholesterol (LDL-C) level of <70 mg/dL appeared to reduce the risk of major cardiovascular (CV) events* following an atherosclerotic ischaemic stroke, according to results of the Treat Stroke to Target trial.
An upsurge in the use of the Impella device has been observed in individuals with acute myocardial infarction complicated by cardiogenic shock (AMI-CS) undergoing percutaneous coronary intervention (PCI); however, mortality and bleeding rates also increased, according to US data presented at AHA 2019.
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.